Histone Modifications and CancerJames E. Audia, Robert M. Campbell|Cold Spring Harbor Perspectives in Biology|2016Cited by 1.1k
Databases for Congenital Heart Defect Public Health Studies Across the LifespanTiffany Riehle‐Colarusso, Rachel Daskalov, Lisa Bergersen et al.|Journal of the American Heart Association|2016Cited by 33
A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancerJohanna C. Bendell, Michael Thomas, Robert M. Campbell et al.|Investigational New Drugs|2019Cited by 30
A Blueprint for an International Cancer Epigenome Consortium. A Report from the AACR Cancer Epigenome Task ForceStephan Beck, Peter A. Jones, B Bernstein et al.|Cancer Research|2012Cited by 25